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Summary 
Before designing a synthetic promoter it can be helpful to think about its final application. Is 
the study purely an in vitro exercise in monitoring short term promoter activity from 
an  episomal vector or does the promoter eventually need to be permanently active and be 
integrated into the genome or perhaps even to function in vivo. The final application will have 
a bearing on promoter design and vector of choice from the start of the study. In this chapter I 
highlight some of the vector attributes to consider and features that should be thought about. 
 
Introduction. 
Promoters are DNA sequences that determine where transcription of a gene by RNA 
polymerase is initiated. In general terms the types of promoters that have been utilised are 
constitutive ubiquitous, tissue specific, regulated promoters (activated by endogenous 
transcription factors) and inducible promoters (transactivators that are ligand/light 
responsive). With the increasing demand for production of recombinant proteins especially as 
pharmaceutical agents, advances in gene therapy and the progress of synthetic biology there 
are increasing applications for promoters in biological systems and the demands on their 
function vary from one application to the next. There are a number of different reasons for 
assembling synthetic promoters which include the generation of compact promoters, 
improving promoter function or designing promoters with additional functionality. In each 
instance it is important to consider the final use of the promoter so that the promoter is 




It is important to consider any limitation on promoter size that will be imposed by the vector 
of choice for gene delivery. Adeno-associated viral vectors have a capacity of approximately 
4.8 Kb (1) and the capacity of self-complementary rAAV is 2.4 Kb (2), so compact synthetic 
promoters will be required, other viral vectors also have size limitations and you should be 
aware of these before progressing. 
 
Core promoter 
Core promoters are a basic feature of all synthetic promoters, they contribute to synthetic 
promoter strength and can have tissue-specific activity. Often they are a simple TATA box 
but can contain other elements, the methods to determine their activity are detailed in Chapter 
7. 
 
Transcription factor binding sites 
In this volume several authors describe the assembly of synthetic promoters through the 
annealing and ligation of oligonucleotides which result in the alignment of desired 
transcription factor binding sites (TFBS) upstream of the core promoter. The sequence bound 
by transcription factors is conserved but will vary to some extent between binding sites. 
When different binding sequences are aligned they can be used to generate a sequence logo 
which is computed based on Shannon entropy {Schneider, 1990 #3659}. In these logos the 
height of the individual letters represents the frequency of a nucleotide in the particular 
position of the alignment. The sequence logo will be informative when selecting nucleotides 
at each position within a TFBS but examination of the literature for functional data is also 
recommended. In many instances spaces will be introduced between TFBS and it may be 
important to screen the resulting spacing sequences using a database such as Transfac® to 
ensure that unwanted TFBS are not inadvertently introduced. 
 
Reporter genes. 
There are a variety of reporter genes that are utilised in order to monitor synthetic promoter 
activity and these are discussed in Chapters 4, 5 and 6. Reporter proteins that are secreted 
from cells have the advantage that promoter activity can be readily monitored from the same 
transfected cells over time, whilst intracellular reporters generally require termination of the 
experiment in order to determine promoter activity. Fluorescent reporters have the added 
advantage that no substrate is required to measure their activity. Most reporter proteins are 
foreign when delivered in vivo and expressing cells will be targeted by the immune system in 
immunocompetent animals. The only exception is secreted alkaline phosphatase, an 
endogenous protein that can be expressed long-term in an immunocompetent host (3). 
 
Cloning approach 
Traditionally cloning will utilise restriction enzymes, in which case it is important to ensure 
that cloning sites are included with the 5’ and 3’ termini of a synthetic promoter and are not 
inadvertently introduced internally within the synthetic promoter sequences during their 
construction. If the aim is to use the same synthetic promoter in several different vectors it 
maybe more efficient to use a recombination cloning system. Firstly, synthetic promoters will 
need to be generated so that they are flanked by the appropriate sequence recognised by the 
specific recombinase. The synthetic promoter is then incubated with the site-specific 
recombinase and the supplied holding vector. It is then easy to shuffle the promoter into a 
variety of ‘destination’/’acceptor’ vectors by recombination cloning without the need to use 
restriction enzymes.  
The recent use of promoters in complex synthetic transcriptional circuits requires careful 
planning as it is necessary to incorporate unique annealing sequences into each subunit to 
ensure correct positioning (Chapter 17). Computer software that can aid in the selection of 
unique nucleotide sequences is described in Chapter 18. 
 
Maximal gene expression  
When high protein expression is required strong promoter activity can be complemented by 
other vector elements that result in replication and amplification of the expression cassette. 
Utilising vectors with a viral origin of replication (Ori), a sequence of DNA at which 
replication is initiated, will result in vector replication in cells expressing appropriate viral 
proteins. In cells that express the Simian Virus 40 (SV40) large tumor antigen (T-Ag) such as 
HEK 293T and Cos7, vectors with the SV40 Ori are episomally replicated. Similarly, cells in 
which Epstein–Barr virus nuclear antigen 1 (EBNA1) is expressed such as HEK 293E will 
replicate vectors containing an Ori-P.  
High levels of gene expression from transfected cells can also be achieved through gene 
amplification of integrated copies of an expression cassette where dihydrofolate reductase 
gene (Dhfr) is co-expressed. This enzyme breaks down Methotrexate (Mtx), by gradually 
increasing the concentration of Mtx in the culture media it is possible to amplify expression 
of both the Dhfr gene and an adjacent expression cassette. This amplification approach is 
commonly used for recombinant protein expression in Chinese hamster ovary (CHO) cells. 
An alternative approach that results in spontaneous initiation of gene amplification in 
transfected cells is achieved by using a vector containing a mammalian replication site and a 
matrix attachment region (MAR) (4). The advantage of this approach is that no viral proteins 
need to be expressed in the cells because the necessary components are DNA elements. 
 
Regulated expression systems 
When working with regulated promoter systems it is optimal that basal expression is minimal 
in the absence of promoter activation. Synthetic regulated promoters are often studied in the 
pGL3 vectors (Promega Corp). In this vector family there is an upstream synthetic poly(A) 
signal/transcriptional pause site (5) to limit promoter activity from the vector backbone which 
is ideal for regulated promoters. The pGL3 vectors do not contain a selection gene expressed 
in eukaryotic cells so if stable clones are required a selection vector should be co-transfected 
with the promoter vector. A selection vector of choice is one that utilises the herpes simplex 
virus thymidine kinase promoter as this is devoid of enhancer activity (ie pTK-Hyg from 
Clontech Laboratories Inc.). The pGL4 family of vectors (Promega Corp) have the advantage 
that there are a reduced number of consensus transcription factor binding sites within the 
backbone and there are versions with co-expressed eukaryotic selection gene expressed.  If 
you clone your promoter in a vector that also expresses a selection gene in eukaryotic cells 
then the promoter that drives its constitutive expression could easily influence the activity of 
the synthetic promoter in the same vector.  
In the case of viral vectors endogenous enhancer and promoter elements could also 
compromise the activity of a cloned synthetic promoter. In retroviral vectors this can be 
surmounted by using self-inactivating vectors (6, 7) in which endogenous enhancer and 
promoter activity is deleted during reverse transcription so that function of the integrated 
synthetic promoter is not compromised (8). 
When regulated expression cassettes are integrated into the genome it is possible that their 
function can be affected by the genetic environment into which they are inserted. This may 
mean that the activity of synthetic promoters could dramatically alter due to interactions with 
enhancer elements neighbouring the integration site. It is possible to overcome these 
influences through the use of an insulator element which has positional enhancer blocking 
activity. The first characterised insulator was found at the 5’ end of the chicken β-globin 
locus and is termed the hypersensitivity site 4 (HS4) insulator or 5’HS4 element (9). 
Insulation activity is mediated by binding of the protein CCCTC-Binding Factor (CTCF) via 
a single site within a 250bp core element (10). Through the interaction of other proteins the 
5’HS4 also has barrier activity which blocks the propagation of heterochromatic structures 
and protects against DNA methylation. 
 
Long-term expression 
In order for synthetic promoters to display long-term activity it is both necessary for the 
vector/expression cassette to be maintained in the cells and the promoter needs to remain 
active.  Through the use of integrating viruses it is possible to ensure that expression cassettes 
are maintained indefinitely, but this can to some extent also been achieved with non-
integrating vectors. Scaffold or MARs (S/MARS) are often found in association with 
chromosomal origins of bidirectional replication and when these DNA elements are linked to 
expression cassettes they can recruit cellular factors to promote episomal replication and 
mitotic stability (11). A vector with an S/MAR-element in association with the SV40 origin 
of replication was shown to replicate at very low copy numbers in CHO cells and was stably 
maintained without selection for more than 100 generations (12). Similarly, when these 
elements were used in a non-integrating lentiviral vector there was no decline in gene 
expression over a 4 week period in 293T cells (13).  
In order to maintain promoter activity one option already mentioned is the 5’HS4 element 
which can potentially protect a promoter sequence from silencing due to methylation. 
Another DNA sequence termed Ubiquitous Chromatin Opening Element (UCOE) also has 
anti-silencing properties by preventing DNA methylation. A recently described minimal 0.7 
kb UCOE (CBX3-UCOE) functioned well in combination with viral and tissue-specific 
promoters without altering promoter specificity (14).  
 
Interaction with the immune system 
Promoters are DNA elements and as such are not immunogenic in vivo but immunogenicity is 
a consideration for other vector elements. If selection genes are expressed from eukaryotic 
promoters then these will be immunogenic in vivo. Such vectors can be modified so that 
foreign genes are not expressed (15) or promoters should be transferred to vectors devoid of 
foreign transgenes. Expression of reporter genes such as EGFP (16) and luciferase (17) are 
immunogenic in immunocompetent mice. Similarly, regulated promoter systems that utilise 
protein components that are foreign will be immunogenic (Chapters 12 and 13), as shown 
with the tetracycline transactivator rtTA (18). 
Most plasmid vectors also contain unmethylated CpG dinucleotides which can activate Toll-
like receptor 9 (TLR9) (19) which could be important if your cell of choice express these 
receptors or if you plan to use the vector in vivo. There are plasmid vectors available that are 
devoid of CpG dinucleotides (InvivoGen) and it is also possible to have genes and vectors 
synthesised in which alternative codons are used so that all CpG dinucleotides are eliminated. 
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